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Abstract
Background: The extent of surgery in patients with unilateral multifocal papillary thyroid microcarcinoma
(UMPTMC) remains to be controversial. Aimed to improve surgical management of UMPTMC, this study was
performed to identify the recurrence of UMPTMC and analyze its predictive factors.
Methods: This study was approved by the Ethical Committee of The First Hospital of the Jilin University, and
written informed consent was given by participants for their clinical records to be used in this study. We
retrospectively analyzed a total of 97 consecutive patients who underwent initial surgery for the treatment of
UMPTMC at The First Hospital of Jilin University, between October 2005 and October 2006.
Results: Altogether, 97 patients of UMPTMC have been enrolled in our study, in which 57 cases were performed
with hemithyroidectomy (HT) while other 40 cases with total thyroidectomy (TT). The sum diameter of all tumors
>1 cm was more frequent in HT group than in TT group (40.35 vs 20%; p = 0.046). Positive central lymph nodes
were found more frequently in the TT patients than in the HT patients (80 vs 59.65%; p = 0.046). Tumor recurrence
was seen more frequently in the HT cases than in the TT cases (26 vs 5%; p = 0.007). The disease-free survival period
was significantly shorter for the HT patients than for the TT patients (p = 0.0059 by the log-rank test). The disease-
free survival rates at 5 and 10 years were 91.23 and 73.68%, respectively, in the HT group and 100 and 92.5%,
respectively, in the TT group. Univariate analysis by Cox’s proportional hazards method showed male gender, sum
diameter of all tumors >1 cm, and central lymph node metastases (CLNM) to be risk factors for recurrence of HT
patients. Male gender and sum diameter >1 cm were factors identified for multivariate analysis by Cox’s
proportional hazards method which yielded risk ratios of 3.037 [CI 1.026–8.988; p = 0.045] and 5.475 [CI 1.389–21.
572; p = 0.015] in the HT group.
Conclusions: In summary, with an increased risk of recurrence, TT may be more reasonable as initial surgery in
UMPTMC, especially with male gender and total tumor diameter greater than 1 cm.
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Background
Papillary thyroid carcinoma (PTC) is the most common
type of thyroid carcinoma, and its incidence has been
increasing around the world due to widespread use of
ultrasonography-guided fine needle aspiration cytology
(FNAC) for small lesions [1–3]. These increases are due
mostly to the increase in the detection of papillary
carcinomas <1 cm in size. PTC measuring 10 mm or less
in the greatest diameter, which is called papillary thyroid
microcarcinoma (PTMC), accounts for 39% of the cases
of thyroid cancer in the USA [3] and 43.1% of the cases
in Korea [4].
However, the extent of surgery in patients with PTMC
continues to be controversial. According to American
Thyroid Association guidelines in 2015, hemithyroidect-
omy (HT) alone is sufficient treatment for small, unifo-
cal, intrathyroidal carcinomas in the absence of prior
head and neck irradiation, familial thyroid carcinoma, or
clinical detectable cervical lymph node metastasis [5].
Total thyroidectomy (TT) is performed when the nodule
is preoperatively confirmed to be malignant in bilateral
lobes by FNAC [5]. Nevertheless, as the 17–87% of PTC
were multifocal [6], there were different opinions on
how to manage the unilateral multifocal PTMC
(UMPTMC). Most surgeons prefer to proceed with TT,
which would be associated with the lowest risk of locor-
egional recurrence. However, the patient would receive
high-dose lifelong thyroid hormone replacement and
take the higher risks of recurrent laryngeal nerve injury
and hypoparathyroidism. Others would be inclined to
persuade UMPTMC patients to accept HT with a
slightly higher risk of locoregional recurrence. Based on
these disputes, we find it important to study the clinical
and pathologic predictors of recurrence in UMPTMC.
Similar studies that have been published on this subject
were rare [7–9]; moreover, most of these reports do not
provide detailed follow-ups of the contralateral nodule.
According to previous studies [7–9], the 10-year recur-
rent and mortality rate of UMPTMC with different
surgery strategies are still unknown; therefore, the cost-
effectiveness of two different surgeries is hard to
evaluate.
To help elucidate these matters further, we developed
a retrospective cohort study of both the HT and TT
strategies in the management of UMPTMC in order to
facilitate decision-making for patients and surgeons.
Firstly, the objective of this study was to identify the
recurrence and mortality of UMPTMC and then to
analyze its predictive factors.
Methods
Patients
This study was approved by the Ethical Committee of
The First Hospital of Jilin University, and written
informed consent was given by participants for their
clinical records to be used in this study. We retrospect-
ively analyzed a total of 673 consecutive patients who
underwent initial surgery for the treatment of thyroid
carcinoma at The First Hospital of Jilin University,
between October 2005 and October 2006. All patients
recruited in the study met the following criteria: (a)
patient information found in a hospital database and (b)
patients with a postoperative pathological diagnosis of
UMPTMC. (c) Patients underwent HT with unilateral
prophylactic central lymph node dissection (CLND) or
TT with bilateral prophylactic CLND. Patients were
excluded from the study if they had pathological types of
thyroid malignancies other than UMPTMC; preoperative
confirmation of bilateral nodule, or obviously extrathyr-
oidal invasion; preoperative confirmation of clinically
positive (ultrasound positive or palpable positive) central
and lateral lymph node; lack of a preoperative examin-
ation; and a history of neck radiotherapy, distant metas-
tasis, and previous thyroid surgery. Finally, this study
enrolled 97 patients with UMPTMC.
Initial treatment and contralateral lobe evaluation
Clinical diagnosis was initially made by examination of
ultrasound and FNAC. Ultrasonography cervical map-
ping was done by experienced, specially trained radiolo-
gist. For the UMPTMC, TT or hemithyroidectomy was
performed according to the patients’ willingness. Before
that, surgeons have explained both the risks and benefits
of each kind of operation and given informed consent
form to patients.
Ultrasound (US) of thyroid and neck lymph node was
performed by two physicians with more than 5-year
experience in thyroid US (Dr. Shuai Xue and Dr. Peisong
Wang); they were blinded to the previously obtained
findings. If their results were inconsistent, another phys-
ician with more than 15-year experience of thyroid US
(Dr. Jia Liu) was asked for consultation.
Clinicopathological variable
Demographic data on patient clinical features (gender,
age at diagnosis), tumor histological characteristics
(diameter of largest tumor, sum diameter of all tumors
(according to histopathology reports), foci number,
primary tumor laterality, extrathyroidal extension, TNM
stage, presence of chronic thyroiditis), and central lymph
node metastases (CLNM) were recorded.
Follow-up, recurrence, and reoperation
Until 2011, TSH-suppressive hormonal therapy was
applied to postoperative patients and all cases did not
receive radioactive iodine therapy. Postoperative physical
examinations were performed every 3–6 months for
10 years. During the period of follow-up, all patients
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underwent ultrasound examinations of the neck as well
as thyroid function test (including thyroglobulin level).
We considered suspicious lymph node as recurrence
using FNAC and washout fluid. Meanwhile, when nod-
ule with diameter larger than 5 mm newly occurred in
the contralateral lobe, FNAC was performed to these pa-
tients. If the result was thyroid carcinoma, we defined it
as recurrence and recommended completion reoperation
at the same time. We took the contralateral lobe and
central and lateral compartment into account as the
local regional recurrence. No patients had distant metas-
tasis. A follow-up at least 10 years post-surgery was
achieved for 89 patients.
Statistical analysis
To identify differences between groups for specific vari-
ables, SPSS version 16 software (SPSS Inc, Chicago, IL)
was used for statistical analysis, which was performed by
Pearson’s chi-square test or Student’s t test. Survival
curves were drawn by Kaplan-Meier method and statisti-
cally analyzed by the log-rank test. To characterize
UMPTMC, univariate analysis was performed by Cox’s
proportional hazards method for disease-free survival.
Factors analyzed were male gender, age (by year), diam-
eter of the largest tumor (millimeters), sum diameter of
all tumors, foci number, primary tumor laterality, extra-
thyroidal extension, TNM stage, presence of chronic thy-
roiditis, and CLNM. Multivariate analysis was performed
by Cox’s proportional hazards method for disease-free
survival and the risk factors. A p value <0.05 was consid-
ered statistically significant.
Results
Altogether, 97 patients of UMPTMC have been enrolled
in our study, in which 57 cases were performed with HT
while other 40 cases with TT. The clinicopathological
characteristics of the UMPTMC (n = 97) are shown in
Table 1. The sum diameter of all tumors >1 cm was
more frequent in HT group than in TT group (40.35 vs
20%; p = 0.046). Positive central lymph nodes were found
more frequently in the TT patients than in the HT
patients (80 vs 59.65%; p = 0.046). Tumor recurrence
was seen more frequently in the HT cases than in the
TT cases (26 vs 5%; p = 0.007). There were no significant
differences between the two groups in terms of age, gen-
der, extrathyroidal extension, diameter of the largest
tumor, foci number, primary tumor laterality, TNM
stage, presence of chronic thyroiditis, average follow-up
period, and the number of disease-related death.
The disease-free survival period was significantly
shorter for the HT patients than for the TT patients (p
= 0.0059 by the log-rank test) (Fig. 1). Details of recur-
rent cases are shown in Table 2. The disease-free
survival rates at 5 and 10 years were 91.23 and 73.68%,
respectively, in the HT group and 100 and 92.5%,
respectively, in the TT group. Survival curves did not
differ statistically between groups (data shown in
Table 1 and Fig. 2).
Table 1 Clinicopathological variable of UMPTMC patients
Characteristics UMPTMC
HT(n = 57, %) TT(n = 40, %) p value
Age (years), mean ± SD 49 ± 10 53 ± 8 0.933
Age cohort
<45 years 23(40.35) 17(42.5) 0.832
≥45 years 34(59.65) 23(57.5)
Sex
Male 12(21.05) 9(22.5) 0.865
Female 45(78.95) 31(77.5)
ETE
Yes 6(10.53) 10(25) 0.059
No 51(89.47) 30(75)
Diameter of the largest tumor
>5 mm 17(29.82) 12(30) 0.985
≤5 mm 40(70.18) 28(70)
Sum diameter of all tumors
>1 cm 23(40.35) 8(20) 0.046
≤1 cm 34(59.65) 32(80)
Foci number
>3 9(15.79) 7(17.5) 0.823
≤3 48(84.21) 33(82.5)
Primary tumor laterality
Left 27(47.37) 19(47.5) 0.990
Right 30(52.63) 21(52.5)
TNM stage
I and II 22(38.60) 12(30)
III and IV 35(61.40) 28(70)
With chronic thyroiditis
Yes 5(8.77) 6(15) 0.167
No 52(91.23) 34(85)
Follow-up period (months)
Average ± SD 126 ± 5 128 ± 3
CLNM 0.822
Yes 34(59.65) 32(80)
No 23(40.35) 8(20) 0.046
Outcome
Tumor recurrence 15/57(26) 2/40(5) 0.007
Contralateral lobe 14(24.56) 0(0)
Central/lateral lymph node 1(1.44) 2(5)
Disease-related death 2/57(3.5) 1/40(2.5) 1.000
SD standard deviation, ETE extrathyroidal extension, CLNM central lymph
node metastases
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There were huge concerns about that most patients
with UMPTMC may have microfoci of PTC in the
contralateral lobe. They may believe that recurrent nod-
ule is not newly occurred in the contralateral lobe but
microfoci which not be detected at the time of diagnosis.
We compared the characteristics of contralateral lobe
between HT and TT groups. Fourteen recurrent cases
were PTMC which is diagnosed by FNAC in HT group;
meanwhile, only two cases had microfoci of PTC in the
contralateral lobe in TT group at the time of diagnosis. p
value was less than 0.05 (p = 0.037), and the difference
was significant. Furthermore, we also analyzed the clini-
copathological features in the contralateral lobe between
HT and TT. The differences were not significant maybe
owing to the small number of patients (data shown in
Table 3).
Univariate analysis by Cox’s proportional hazards
method showed male gender, sum diameter of all tumors
>1 cm, and CLNM to be risk factors for recurrence of
HT patients (Table 4). Age, extrathyroidal extension,
diameter of the largest tumor, foci number, primary
Fig. 1 The disease-free survival rates at 5 and 10 years were 91.23 and
73.68%, respectively, in the HT group and 100 and 92.5%, respectively,
in the TT group. The disease-free survival period was significantly
shorter for the HT patients than for the TT patients (p = 0.0059 by the
log-rank test)
Table 2 The characteristics of recurrent cases



















1 42/F 0.8 + 4 L I 1.9 1/6 + HT 5 Contralateral lobe
2 56/M 0.4 − 2 L III 0.8 3/5 + HT 78 Contralateral lobe
3 67/F 0.5 − 4 L III 1.8 1/6 + HT 25 Contralateral lobe
4 34/M 0.5 − 2 L I 0.7 1/6 + HT 92 Contralateral lobe
5 37/M 0.7 − 3 R I 1.7 0/5 − HT 35 Contralateral lobe
6 71/F 0.5 − 2 L III 0.9 4/5 + HT 37 Ipsilateral central
7 65/F 0.4 − 3 L I 1.1 0/4 − HT 48 Contralateral lobe
8 43/M 0.3 − 3 R I 0.9 1/5 + HT 63 Contralateral lobe
9 47/M 0.9 − 2 L III 1.6 1/8 + HT 66 Contralateral lobe
10 48/F 0.4 − 2 R III 0.7 3/7 + HT 73 Contralateral lobe
11 51/M 0.4 − 5 R III 1.9 3/5 + HT 83 Contralateral lobe
12 52/F 0.9 + 2 R III 1.3 2/6 + HT 89 Contralateral lobe
13 24/M 0.8 − 4 R I 2.2 2/9 + HT 103 Contralateral lobe
14 39/F 0.8 + 3 R I 1.1 3/11 + HT 91 Contralateral lobe
15 65/M 0.3 − 2 R III 0.6 1/8 + HT 67 Contralateral lobe
16 48/F 0.5 + 3 L IV 1.4 1/11 + TT 81 Contralateral central
17 66/F 0.5 + 3 R IV 1.4 2/4 + TT 102 Ipsilateral lateral
ETE extrathyroid extension, CLNR central lymph node ratio, CLNM central lymph node metastasis
Fig. 2 Disease-specific mortality did not differ statistically
between groups
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tumor laterality, TNM stage, and presence of chronic
thyroiditis were not predictors of recurrence. The risk
ratio for male gender, sum diameter >1 cm, and positive
CLNM were 5.676 [confidence interval (CI) 2.034–
15.839; p = 0.001], 9.072 [CI 2.533–32.491; p = 0.001],
and 4.951 [CI 1.114–21.998; p = 0.036] in the HT group.
No other risk ratios obtained were of interest. Male gen-
der and sum diameter >1 cm were factors identified for
multivariate analysis by Cox’s proportional hazards
method (Table 5) which yielded risk ratios of 3.037 [CI
1.026–8.988; p = 0.045] and 5.475 [CI 1.389–21.572; p =
0.015] in the HT group. Accordingly, male gender and
sum diameter >1 cm were shown to be independent
predictors of disease-free survival.
Discussion
Many studies have found that multifocal PTC comprised
a more aggressive form of PTC since it was associated
with more frequent N1a/N1b disease and occurs more
frequently in T3/T4 patients [10]. TT was recommended
to multifocal PTC patients for the reason multifocality
was associated with an increased risk of disease recur-
rence or persistence [11, 12]. Nevertheless, PTMC was
an inert form of PTC with low risk of recurrence and
good prognosis. Therefore, how to manage the patients
with UMPTMC remains controversial until now.
Therefore, we investigate clinical and pathologic char-
acteristics of these two group patients, who received HT
and TT, respectively. Compared between two groups, we
find the disease-free survival period was significantly
shorter for the HT patients than for the TT patients (p
= 0.0059 by the log-rank test). Some researches demon-
strated most PTMCs had excellent prognosis, and multi-
focality did not appear to have significant clinical
importance in these tumors [12, 13]. Presence of hetero-
geneity in clinicopathological features and lack of long-
time follow-ups lead to the identical disease-free survival
period between unifocal and multifocal PTMC. Consist-
ent with our study, Pyo et al. reported that tumor
multifocality was significantly correlated with tumor
recurrence in PTMCs (odds ratio, 2.002; 95% confidence
interval, 1.475 to 2.719, p < 0.001) [14]. With an
increased risk of recurrence, HT is not a reasonable
operation for UMPTMC. If we recommend TT for all
UMPTMCs, the patients would be informed about the
need for lifelong thyroid hormone replacement and the
risks of recurrent laryngeal nerve injury and hypopara-
thyroidism. Accordingly, by univariate and multivariate
analysis by Cox’s proportional hazards methods, we try
to ascertain clinical and pathologic predictors of recur-
rence in UMPTMC.
In our study, univariate analysis showed male gender,
sum diameter of all tumors >1 cm, and CLNM to be risk
factors for recurrence of HT patients, as reported in pre-
vious studies by Kiriakopoulos et al. [10] and Huang et
al. [15], although they focused on multifocal PTC. Kiria-
kopoulos et al. also found foci number correlates with
male gender and lymph node metastases [10]. According
to a consensus report of the European Society of Endo-
crine Surgeons, they recommended bilateral prophylactic
CLND for patients with total tumor diameter (sum of
the largest diameter of all foci) greater than 1 cm,
Table 3 Clinicopathological variable of contralateral lobe
Characteristics Contralateral lobe
HT (n = 57) TT (n = 40) p value
PTMC
Yes 14 2
Tumor size (mm) mean ± SD 0.75 ± 0.23 0.21 ± 0.02 0.085
Microscopic ETE (+) 2 0 0.510
Multifocal (+) 3 0 0.265
With chronic thyroiditis (+) 1 0 1.000
No 42 38 0.037a
Benign nodule
Yes 7 10
No 50 30 0.105
SD standard deviation, PTMC papillary thyroid microcarcinoma, ETE
extrathyroidal extension
aComparison on the PTMC rate in the contralateral lobe between HT and TT
Table 4 Univariate analysis by Cox’s proportional hazards
method for disease-free survival
Factors analyzed HT patients
Risk ratio(CI) p value
Age (years) 1.112(0.395–3.130) 0.840
Male gender 5.676(2.034–15.839) 0.001
ETE 0.041(0.000–40.879) 0.365
Diameter of the largest tumor 1.688(0.601–4.743) 0.321
Sum diameter of all tumors 9.072(2.533–32.491) 0.001
Foci number 2.191(0.697–6.886) 0.179
Primary tumor laterality 0.889(0.322–2.452) 0.820
TNM stage 1.131(0.386–3.312) 0.822
With chronic thyroiditis 1.638(0.369–7.261) 0.516
CLNM 4.951(1.114–21.998) 0.036
ETE extrathyroidal extension, CLNM central lymph node metastases
Table 5 Multivariate analysis by Cox’s proportional hazards
method for disease-free survival
Factors analyzed HT patients
Risk ratio (CI) p value
Male gender 3.037(1.026–8.988) 0.045
Sum diameter of all tumors 5.475(1.389–21.572) 0.015
CLNM 2.205(0.446–10.912) 0.332
CLNM central lymph node metastases
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because the frequency of subclinical CLNM is higher in
multifocal PTC. Combining literatures on multifocal
PTC and our study, we believe TT should be considered
for UMPTMC, especially with male gender and total
tumor diameter greater than 1 cm [6].
The gene(s) responsible for multifocal PTC have not
yet been identified, and this disorder is now being inves-
tigated on a molecular level. Several researches found
most of the patients with multifocal PTC had the
BRAFV600E mutation in one or more tumor foci and all
BRAFV600E-positive multifocal PTC showed more
aggressive features [16, 17]. Moreover, many studies have
investigated multifocal PTC clonality through a number
of approaches, including X-chromosome inactivation,
BRAFmutation, RET rearrangements, loss of heterozygos-
ity, or allelic imbalances of distinct cancer foci [17–19].
High rate of independent clonality found in multifocal
PTC patients lends support to the notion of field canceri-
zation, whereby carcinogenic agents would affect a wide
range of genetic susceptible cells, resulting in their simul-
taneous transformation [19]. Based on this theory, the
contralateral lobe of UMPTMC has higher risk of recur-
rence attribute to genetic predispositions, environmental
exposures, and epidemiological factors. That explains why
we recommend TT for UMPTMC, especially with male
gender and total tumor diameter greater than 1 cm.
Our study has several limitations. The first limitation
is the small number of patients in the study population;
due to the incidence of UMPTMC is low, and we want
long duration of follow-up, we just summarized patients
between October 2005 and October 2006. The second
limitation is that until 2011, TSH-suppressive hormonal
therapy was applied to postoperative patients and all
cases did not receive radioactive iodine ablation. At that
time, there was no guideline in China, which we could
follow to recommend TSH-suppressive hormonal and
radioactive iodine therapy. Finally, we did not use radio-
iodine whole body scan and PET scan routinely for all
the TT patients. This might have some influence on the
accuracy of diagnosis of recurrence in TT group, espe-
cially distant metastasis. However, the postoperative
patients with negative US and thyroglobulin results are
less likely to have positive radioiodine and PET scan.
Despite these limitations, our study has important impli-
cations for UMPTMC management and provides signifi-
cant information for PTMC guideline formation.
Furthermore, to our knowledge, this study is the first
report to recommend the optimal surgery strategy for
UMPTMC patients.
Conclusions
Taken together, with an increased risk of recurrence, TT
may be more reasonable as initial surgery in UMPTMC,
especially with male gender and total tumor diameter
greater than 1 cm. A multicentric pragmatic randomized
controlled clinical trial with large population is needed
to assess the effects on recurrence, quality of life, and
cost-effectiveness outcomes of different treatments and
follow-up regimen for UMPTMC.
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